Long-Term Prognosis of Acute Myeloid Leukemia According to the New Genetic Risk Classification of the European LeukemiaNet Recommendations: Evaluation of the Proposed Reporting System | Zendy

Christoph Röllig | Zendy; Martin Bornhäuser | Zendy; Christian Thiede | Zendy; Franziska Taube | Zendy; Michael Krämer | Zendy; Brigitte Mohr | Zendy; Walter E. Aulitzky | Zendy; H. Bodenstein | Zendy; HansJoachim Tischler | Zendy; Reingard Stuhlmann | Zendy; Ulrich S. Schuler | Zendy; Friedrich Stölzel | Zendy; Malte von Bonin | Zendy; Hannes Wandt | Zendy; Kerstin SchäferEckart | Zendy; Markus Schaich | Zendy; Gerhard Ehninger | Zendy

Open Access

Long-Term Prognosis of Acute Myeloid Leukemia According to the New Genetic Risk Classification of the European LeukemiaNet Recommendations: Evaluation of the Proposed Reporting System

Author(s) -

Christoph Röllig,

Martin Bornhäuser,

Christian Thiede,

Franziska Taube,

Michael Krämer,

Brigitte Mohr,

Walter E. Aulitzky,

H. Bodenstein,

HansJoachim Tischler,

Reingard Stuhlmann,

Ulrich S. Schuler,

Friedrich Stölzel,

Malte von Bonin,

Hannes Wandt,

Kerstin SchäferEckart,

Markus Schaich,

Gerhard Ehninger

Publication year - 2011

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2010.32.8500

Subject(s) - medicine , myeloid leukemia , cohort , adverse effect , log rank test , acute leukemia , pediatrics , oncology , proportional hazards model , leukemia

The current European LeukemiaNet (ELN) recommendations for acute myeloid leukemia (AML) propose a new risk reporting system, integrating molecular and cytogenetic factors and subdividing the large heterogenous group of intermediate-risk patients into intermediate-I (IR-I) and intermediate-II (IR-II). We assessed the prognostic value of the new risk classification in a large cohort of patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research